Literature DB >> 31611261

RELMα Licenses Macrophages for Damage-Associated Molecular Pattern Activation to Instigate Pulmonary Vascular Remodeling.

Qing Lin1, Chunling Fan1, John T Skinner1, Elizabeth N Hunter1, Andrew A Macdonald1, Peter B Illei2, Kazuyo Yamaji-Kegan1, Roger A Johns3.   

Abstract

Pulmonary hypertension (PH) is a debilitating disease characterized by remodeling of the lung vasculature. In rodents, resistin-like molecule-α (RELMα, also known as HIMF or FIZZ1) can induce PH, but the signaling mechanisms are still unclear. In this study, we used human lung samples and a hypoxia-induced mouse model of PH. We found that the human homolog of RELMα, human (h) resistin, is upregulated in macrophage-like inflammatory cells from lung tissues of patients with idiopathic PH. Additionally, at PH onset in the mouse model, we observed RELMα-dependent lung accumulation of macrophages that expressed high levels of the key damage-associated molecular pattern (DAMP) molecule high-mobility group box 1 (HMGB1) and its receptor for advanced glycation end products (RAGE). In vitro, RELMα/hresistin-induced macrophage-specific HMGB1/RAGE expression and facilitated HMGB1 nucleus-to-cytoplasm translocation and extracellular secretion. Mechanistically, hresistin promoted HMGB1 posttranslational lysine acetylation by preserving the NAD+-dependent deacetylase sirtuin (Sirt) 1 in human macrophages. Notably, the hresistin-stimulated macrophages promoted apoptosis-resistant proliferation of human pulmonary artery smooth muscle cells in an HMGB1/RAGE-dependent manner. In the mouse model, RELMα also suppressed the Sirt1 signal in pulmonary macrophages in the early posthypoxic period. Notably, recruited macrophages in the lungs of these mice carried the RELMα binding partner Bruton tyrosine kinase (BTK). hResistin also mediated the migration of human macrophages by activating BTK in vitro. Collectively, these data reveal a vascular-immune cellular interaction in the early PH stage and suggest that targeting RELMα/DAMP-driven macrophages may offer a promising strategy to treat PH and other related vascular inflammatory diseases.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31611261      PMCID: PMC6864303          DOI: 10.4049/jimmunol.1900535

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

1.  Soluble RAGE and the RAGE ligands HMGB1 and S100A12 in critical illness: impact of glycemic control with insulin and relation with clinical outcome.

Authors:  Catherine Ingels; Inge Derese; Pieter J Wouters; Greet Van den Berghe; Ilse Vanhorebeek
Journal:  Shock       Date:  2015-02       Impact factor: 3.454

2.  High mobility group box 1 skews macrophage polarization and negatively influences phagocytosis of apoptotic cells.

Authors:  Fleur Schaper; Karina de Leeuw; Gerda Horst; Hendrika Bootsma; Pieter C Limburg; Peter Heeringa; Marc Bijl; Johanna Westra
Journal:  Rheumatology (Oxford)       Date:  2016-09-15       Impact factor: 7.580

3.  Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule.

Authors:  Claudia Schlueter; Holger Weber; Britta Meyer; Piere Rogalla; Kerstin Röser; Sven Hauke; Jörn Bullerdiek
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

4.  Production of recombinant human HMGB1 and anti-HMGB1 rabbit serum.

Authors:  Qing Lin; Jiazhu Fang; Dan Fang; Bing Li; Hongyan Zhou; Shao Bo Su
Journal:  Int Immunopharmacol       Date:  2011-01-19       Impact factor: 4.932

5.  Comparative studies of resistin expression and phylogenomics in human and mouse.

Authors:  Rong-Ze Yang; Qing Huang; Aihua Xu; John C McLenithan; Jonathan A Eisen; Alan R Shuldiner; Serhan Alkan; Da-Wei Gong; Jonathan A Eison
Journal:  Biochem Biophys Res Commun       Date:  2003-10-24       Impact factor: 3.575

6.  Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein.

Authors:  Jong Sung Park; Daiva Svetkauskaite; Qianbin He; Jae-Yeol Kim; Derek Strassheim; Akitoshi Ishizaka; Edward Abraham
Journal:  J Biol Chem       Date:  2003-12-04       Impact factor: 5.157

7.  Plasma Levels of Receptor for Advanced Glycation End-Products and High-Mobility Group Box 1 in Patients With Pulmonary Hypertension.

Authors:  Satoshi Suzuki; Kazuhiko Nakazato; Koichi Sugimoto; Akiomi Yoshihisa; Takayoshi Yamaki; Hiroyuki Kunii; Hitoshi Suzuki; Shu-Ichi Saitoh; Yasuchika Takeishi
Journal:  Int Heart J       Date:  2016-03-11       Impact factor: 1.862

8.  Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMalpha) induces the vascular and hemodynamic changes of pulmonary hypertension.

Authors:  Daniel J Angelini; Qingning Su; Kazuyo Yamaji-Kegan; Chunling Fan; John T Skinner; Hunter C Champion; Michael T Crow; Roger A Johns
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-01-09       Impact factor: 5.464

Review 9.  Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1).

Authors:  Judy R van Beijnum; Wim A Buurman; Arjan W Griffioen
Journal:  Angiogenesis       Date:  2008-02-09       Impact factor: 9.596

10.  Differential responses of Trans-Resveratrol on proliferation of neural progenitor cells and aged rat hippocampal neurogenesis.

Authors:  Vivek Kumar; Ankita Pandey; Sadaf Jahan; Rajendra Kumar Shukla; Dipak Kumar; Akriti Srivastava; Shripriya Singh; Chetan Singh Rajpurohit; Sanjay Yadav; Vinay Kumar Khanna; Aditya Bhushan Pant
Journal:  Sci Rep       Date:  2016-06-23       Impact factor: 4.379

View more
  9 in total

Review 1.  Resistin family proteins in pulmonary diseases.

Authors:  Qing Lin; Roger A Johns
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-06-17       Impact factor: 5.464

2.  Systemic evaluation and localization of resistin expression in normal human tissues by a newly developed monoclonal antibody.

Authors:  Qing Lin; Shari A Price; John T Skinner; Bin Hu; Chunling Fan; Kazuyo Yamaji-Kegan; Roger A Johns
Journal:  PLoS One       Date:  2020-07-01       Impact factor: 3.240

3.  The six-transmembrane protein Stamp2 ameliorates pulmonary vascular remodeling and pulmonary hypertension in mice.

Authors:  Mehreen Batool; Eva M Berghausen; Mario Zierden; Marius Vantler; Ralph T Schermuly; Stephan Baldus; Stephan Rosenkranz; Henrik Ten Freyhaus
Journal:  Basic Res Cardiol       Date:  2020-11-13       Impact factor: 17.165

Review 4.  Dysregulated Immunity in Pulmonary Hypertension: From Companion to Composer.

Authors:  Teresa C Funk-Hilsdorf; Felix Behrens; Jana Grune; Szandor Simmons
Journal:  Front Physiol       Date:  2022-02-17       Impact factor: 4.566

5.  Inhibition of Bruton's Tyrosine Kinase Alleviates Monocrotaline-Induced Pulmonary Arterial Hypertension by Modulating Macrophage Polarization.

Authors:  Min Yu; Xuecheng Wu; Liyao Peng; Mingxia Yang; Hong Zhou; Jian Xu; Jingjing Wang; Hong Wang; Weiping Xie; Hui Kong
Journal:  Oxid Med Cell Longev       Date:  2022-08-29       Impact factor: 7.310

Review 6.  Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective.

Authors:  Thomas Koudstaal; Karin A Boomars; Mirjam Kool
Journal:  J Clin Med       Date:  2020-02-19       Impact factor: 4.241

Review 7.  The Role of Hypoxia-Induced Mitogenic Factor in Organ-Specific Inflammation in the Lung and Liver: Key Concepts and Gaps in Knowledge Regarding Molecular Mechanisms of Acute or Immune-Mediated Liver Injury.

Authors:  Sananda Pai; Dolores B Njoku
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

Review 8.  Hypoxia-Induced Mitogenic Factor: A Multifunctional Protein Involved in Health and Disease.

Authors:  Moyang Lv; Wenjuan Liu
Journal:  Front Cell Dev Biol       Date:  2021-07-15

9.  Macrophage-Regulatory T Cell Interactions Promote Type 2 Immune Homeostasis Through Resistin-Like Molecule α.

Authors:  Jiang Li; Sang Yong Kim; Nancy M Lainez; Djurdjica Coss; Meera G Nair
Journal:  Front Immunol       Date:  2021-07-19       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.